Selected research
Industry Research
Ranitidine (Zantac) Industry Research Report 2026
Market perspective
The global Ranitidine (Zantac) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Ranitidine (Zantac) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Ranitidine (Zantac) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Ranitidine (Zantac) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Ranitidine (Zantac) include Sanofi-Aventis, GlaxoSmithKline, Hi-Tech Pharmacal Co., Sun Pharma, Mylan Pharmaceuticals Inc. (and Mylan Laboratories), Dr. Reddy’s Laboratories Inc., Sandoz Inc. (part of Novartis AG), Strides (and Strides Arcolab international) and Geri-Care Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Ranitidine (Zantac) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ranitidine (Zantac) Market by Company
Sanofi-Aventis
GlaxoSmithKline
Hi-Tech Pharmacal Co.
Sun Pharma
Mylan Pharmaceuticals Inc. (and Mylan Laboratories)
Dr. Reddy’s Laboratories Inc.
Sandoz Inc. (part of Novartis AG)
Strides (and Strides Arcolab international)
Geri-Care Pharmaceuticals
PAI Holdings, LLC
Teva Pharmaceuticals
Granules Pharmaceuticals Inc.
Glenmark Pharmaceuticals (and Glenmark Generics)
Apotex Inc. (and Apotex Corporation)
Hikma Pharmaceuticals (West-ward Pharmaceuticals)
Ranitidine (Zantac) Segment by Type
Ranitidine Capsule
Ranitidine Oral Tablet
Ranitidine Injectable Solution
Ranitidine Oral Syrup
Ranitidine (Zantac) Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Ranitidine (Zantac) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ranitidine (Zantac) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ranitidine (Zantac) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ranitidine (Zantac).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Ranitidine (Zantac) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Ranitidine (Zantac) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Ranitidine (Zantac) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ranitidine Capsule
- Ranitidine Oral Tablet
- Ranitidine Injectable Solution
- Ranitidine Oral Syrup
Applications
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Companies covered
- Sanofi-Aventis
- GlaxoSmithKline
- Hi-Tech Pharmacal Co.
- Sun Pharma
- Mylan Pharmaceuticals Inc. (and Mylan Laboratories)
- Dr. Reddy’s Laboratories Inc.
- Sandoz Inc. (part of Novartis AG)
- Strides (and Strides Arcolab international)
- Geri-Care Pharmaceuticals
- PAI Holdings, LLC
- Teva Pharmaceuticals
- Granules Pharmaceuticals Inc.
- Glenmark Pharmaceuticals (and Glenmark Generics)
- Apotex Inc. (and Apotex Corporation)
- Hikma Pharmaceuticals (West-ward Pharmaceuticals)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Ranitidine (Zantac) Market Size (2021-2032)
- 2.2.2 Global Ranitidine (Zantac) Sales (2021-2032)
- 2.2.3 Global Ranitidine (Zantac) Market Average Price (2021-2032)
- 2.3 Ranitidine (Zantac) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ranitidine Capsule
- 2.3.3 Ranitidine Oral Tablet
- 2.3.4 Ranitidine Injectable Solution
- 2.3.5 Ranitidine Oral Syrup
- 2.4 Ranitidine (Zantac) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacy
- 2.4.3 Retail Pharmacy
- 2.4.4 Online Pharmacy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Ranitidine (Zantac) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Ranitidine (Zantac) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Ranitidine (Zantac) Revenue of Manufacturers (2021-2026)
- 3.4 Global Ranitidine (Zantac) Average Price by Manufacturers (2021-2026)
- 3.5 Global Ranitidine (Zantac) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Ranitidine (Zantac), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Ranitidine (Zantac), Product Type & Application
- 3.8 Global Manufacturers of Ranitidine (Zantac), Established Date
- 3.9 Global Ranitidine (Zantac) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi-Aventis
- 4.1.1 Sanofi-Aventis Company Information
- 4.1.2 Sanofi-Aventis Business Overview
- 4.1.3 Sanofi-Aventis Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi-Aventis Ranitidine (Zantac) Product Portfolio
- 4.1.5 Sanofi-Aventis Recent Developments
- 4.2 GlaxoSmithKline
- 4.2.1 GlaxoSmithKline Company Information
- 4.2.2 GlaxoSmithKline Business Overview
- 4.2.3 GlaxoSmithKline Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Ranitidine (Zantac) Product Portfolio
- 4.2.5 GlaxoSmithKline Recent Developments
- 4.3 Hi-Tech Pharmacal Co.
- 4.3.1 Hi-Tech Pharmacal Co. Company Information
- 4.3.2 Hi-Tech Pharmacal Co. Business Overview
- 4.3.3 Hi-Tech Pharmacal Co. Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hi-Tech Pharmacal Co. Ranitidine (Zantac) Product Portfolio
- 4.3.5 Hi-Tech Pharmacal Co. Recent Developments
- 4.4 Sun Pharma
- 4.4.1 Sun Pharma Company Information
- 4.4.2 Sun Pharma Business Overview
- 4.4.3 Sun Pharma Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sun Pharma Ranitidine (Zantac) Product Portfolio
- 4.4.5 Sun Pharma Recent Developments
- 4.5 Mylan Pharmaceuticals Inc. (and Mylan Laboratories)
- 4.5.1 Mylan Pharmaceuticals Inc. (and Mylan Laboratories) Company Information
- 4.5.2 Mylan Pharmaceuticals Inc. (and Mylan Laboratories) Business Overview
- 4.5.3 Mylan Pharmaceuticals Inc. (and Mylan Laboratories) Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mylan Pharmaceuticals Inc. (and Mylan Laboratories) Ranitidine (Zantac) Product Portfolio
- 4.5.5 Mylan Pharmaceuticals Inc. (and Mylan Laboratories) Recent Developments
- 4.6 Dr. Reddy’s Laboratories Inc.
- 4.6.1 Dr. Reddy’s Laboratories Inc. Company Information
- 4.6.2 Dr. Reddy’s Laboratories Inc. Business Overview
- 4.6.3 Dr. Reddy’s Laboratories Inc. Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Dr. Reddy’s Laboratories Inc. Ranitidine (Zantac) Product Portfolio
- 4.6.5 Dr. Reddy’s Laboratories Inc. Recent Developments
- 4.7 Sandoz Inc. (part of Novartis AG)
- 4.7.1 Sandoz Inc. (part of Novartis AG) Company Information
- 4.7.2 Sandoz Inc. (part of Novartis AG) Business Overview
- 4.7.3 Sandoz Inc. (part of Novartis AG) Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sandoz Inc. (part of Novartis AG) Ranitidine (Zantac) Product Portfolio
- 4.7.5 Sandoz Inc. (part of Novartis AG) Recent Developments
- 4.8 Strides (and Strides Arcolab international)
- 4.8.1 Strides (and Strides Arcolab international) Company Information
- 4.8.2 Strides (and Strides Arcolab international) Business Overview
- 4.8.3 Strides (and Strides Arcolab international) Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Strides (and Strides Arcolab international) Ranitidine (Zantac) Product Portfolio
- 4.8.5 Strides (and Strides Arcolab international) Recent Developments
- 4.9 Geri-Care Pharmaceuticals
- 4.9.1 Geri-Care Pharmaceuticals Company Information
- 4.9.2 Geri-Care Pharmaceuticals Business Overview
- 4.9.3 Geri-Care Pharmaceuticals Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Geri-Care Pharmaceuticals Ranitidine (Zantac) Product Portfolio
- 4.9.5 Geri-Care Pharmaceuticals Recent Developments
- 4.10 PAI Holdings, LLC
- 4.10.1 PAI Holdings, LLC Company Information
- 4.10.2 PAI Holdings, LLC Business Overview
- 4.10.3 PAI Holdings, LLC Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 PAI Holdings, LLC Ranitidine (Zantac) Product Portfolio
- 4.10.5 PAI Holdings, LLC Recent Developments
- 4.11 Teva Pharmaceuticals
- 4.11.1 Teva Pharmaceuticals Company Information
- 4.11.2 Teva Pharmaceuticals Business Overview
- 4.11.3 Teva Pharmaceuticals Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Teva Pharmaceuticals Ranitidine (Zantac) Product Portfolio
- 4.11.5 Teva Pharmaceuticals Recent Developments
- 4.12 Granules Pharmaceuticals Inc.
- 4.12.1 Granules Pharmaceuticals Inc. Company Information
- 4.12.2 Granules Pharmaceuticals Inc. Business Overview
- 4.12.3 Granules Pharmaceuticals Inc. Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Granules Pharmaceuticals Inc. Ranitidine (Zantac) Product Portfolio
- 4.12.5 Granules Pharmaceuticals Inc. Recent Developments
- 4.13 Glenmark Pharmaceuticals (and Glenmark Generics)
- 4.13.1 Glenmark Pharmaceuticals (and Glenmark Generics) Company Information
- 4.13.2 Glenmark Pharmaceuticals (and Glenmark Generics) Business Overview
- 4.13.3 Glenmark Pharmaceuticals (and Glenmark Generics) Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Glenmark Pharmaceuticals (and Glenmark Generics) Ranitidine (Zantac) Product Portfolio
- 4.13.5 Glenmark Pharmaceuticals (and Glenmark Generics) Recent Developments
- 4.14 Apotex Inc. (and Apotex Corporation)
- 4.14.1 Apotex Inc. (and Apotex Corporation) Company Information
- 4.14.2 Apotex Inc. (and Apotex Corporation) Business Overview
- 4.14.3 Apotex Inc. (and Apotex Corporation) Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Apotex Inc. (and Apotex Corporation) Ranitidine (Zantac) Product Portfolio
- 4.14.5 Apotex Inc. (and Apotex Corporation) Recent Developments
- 4.15 Hikma Pharmaceuticals (West-ward Pharmaceuticals)
- 4.15.1 Hikma Pharmaceuticals (West-ward Pharmaceuticals) Company Information
- 4.15.2 Hikma Pharmaceuticals (West-ward Pharmaceuticals) Business Overview
- 4.15.3 Hikma Pharmaceuticals (West-ward Pharmaceuticals) Ranitidine (Zantac) Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Hikma Pharmaceuticals (West-ward Pharmaceuticals) Ranitidine (Zantac) Product Portfolio
- 4.15.5 Hikma Pharmaceuticals (West-ward Pharmaceuticals) Recent Developments
5 Global Ranitidine (Zantac) Market Scenario by Region
- 5.1 Global Ranitidine (Zantac) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Ranitidine (Zantac) Sales by Region: 2021-2032
- 5.2.1 Global Ranitidine (Zantac) Sales by Region: 2021-2026
- 5.2.2 Global Ranitidine (Zantac) Sales by Region: 2027-2032
- 5.3 Global Ranitidine (Zantac) Revenue by Region: 2021-2032
- 5.3.1 Global Ranitidine (Zantac) Revenue by Region: 2021-2026
- 5.3.2 Global Ranitidine (Zantac) Revenue by Region: 2027-2032
- 5.4 North America Ranitidine (Zantac) Market Facts & Figures by Country
- 5.4.1 North America Ranitidine (Zantac) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Ranitidine (Zantac) Sales by Country (2021-2032)
- 5.4.3 North America Ranitidine (Zantac) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Ranitidine (Zantac) Market Facts & Figures by Country
- 5.5.1 Europe Ranitidine (Zantac) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Ranitidine (Zantac) Sales by Country (2021-2032)
- 5.5.3 Europe Ranitidine (Zantac) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Ranitidine (Zantac) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Ranitidine (Zantac) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Ranitidine (Zantac) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Ranitidine (Zantac) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Ranitidine (Zantac) Market Facts & Figures by Country
- 5.7.1 South America Ranitidine (Zantac) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Ranitidine (Zantac) Sales by Country (2021-2032)
- 5.7.3 South America Ranitidine (Zantac) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Ranitidine (Zantac) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Ranitidine (Zantac) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Ranitidine (Zantac) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Ranitidine (Zantac) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Ranitidine (Zantac) Sales by Type (2021-2032)
- 6.1.1 Global Ranitidine (Zantac) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Ranitidine (Zantac) Sales Market Share by Type (2021-2032)
- 6.2 Global Ranitidine (Zantac) Revenue by Type (2021-2032)
- 6.2.1 Global Ranitidine (Zantac) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Ranitidine (Zantac) Revenue Market Share by Type (2021-2032)
- 6.3 Global Ranitidine (Zantac) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Ranitidine (Zantac) Sales by Application (2021-2032)
- 7.1.1 Global Ranitidine (Zantac) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Ranitidine (Zantac) Sales Market Share by Application (2021-2032)
- 7.2 Global Ranitidine (Zantac) Revenue by Application (2021-2032)
- 7.2.1 Global Ranitidine (Zantac) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Ranitidine (Zantac) Revenue Market Share by Application (2021-2032)
- 7.3 Global Ranitidine (Zantac) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Ranitidine (Zantac) Value Chain Analysis
- 8.1.1 Ranitidine (Zantac) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Ranitidine (Zantac) Production Mode & Process
- 8.2 Ranitidine (Zantac) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Ranitidine (Zantac) Distributors
- 8.2.3 Ranitidine (Zantac) Customers
9 Global Ranitidine (Zantac) Analyzing Market Dynamics
- 9.1 Ranitidine (Zantac) Industry Trends
- 9.2 Ranitidine (Zantac) Industry Drivers
- 9.3 Ranitidine (Zantac) Industry Opportunities and Challenges
- 9.4 Ranitidine (Zantac) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst